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Abstract 
Persistent HPV infection alone is not sufficient for cervical cancer development, which requires 
additional molecular alterations for tumor progression and metastasis ultimately leading to a lethal 
disease. In this study, we performed a comprehensive analysis of HER family receptor alterations in 
cervical adenocarcinoma. We detected overexpression of HER protein, mainly HER2, which was 
an independent prognostic marker for these patients. By using in vitro and in vivo approaches, we 
provided evidence that HER inhibitors, allitinib and lapatinib, were effective in reducing cervical 
cancer aggressiveness. Furthermore, combination of these drugs with glucose uptake blockers 
could overcome the putative HIF1-α-mediated resistance to HER-targeted therapies. Thus, we 
propose that the use of HER inhibitors in association with glycolysis blockers can be a potentially 
effective treatment option for HER-positive cervical cancer patients. 
Key words: ErbB, EGFR, HER2, cervical cancer, prognosis, targeted therapy. 
Introduction 
Cervical cancer is a major malignant disease 
among women worldwide and is estimated to account 
for 8% of the total cancer related mortality. Around 
500,000 new cases of cervical cancer and 250,000 
cervical cancer-related deaths occur worldwide every 
year [1]. Screenings with cytology and high-risk 
human papillomavirus (HPV) DNA testing have 
reduced the incidence and mortality of this disease. 
However, women who do not have access to health 
care and those living in underserved areas remain at 
high risk of death from this disease [2]. Although 
early-stage disease can be cured by radical surgery 
and locally advanced disease by chemo-radiotherapy, 
women with metastatic and non-operable recurrent 
disease have few treatment options [2]. 
Platinum-based chemotherapy in this setting is 
palliative and is associated with median overall 
survival of 8 to 12 months [2-4]. Thus, a deeper 
molecular understanding and effective therapeutic 
strategies are desperately needed for the treatment of 
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recurrent/metastatic cervical cancer. 
Receptor tyrosine kinases (RTKs) are 
membrane-spanning proteins that possess a 
ligand-controlled intracellular kinase activity [5]. 
Deregulation of RTKs due to overexpression, 
mutation, amplification or autocrine stimulation has 
been causally linked to cancer development and 
progression [5]. We had been studying the molecular 
pathology of cervical cancer, with emphasis on RTK 
alterations and reported important alterations in KIT, 
PDGFRA, VEGFR2 and EGFR family of receptors [3, 
6-8]. RTKs and intracellular signaling pathways 
constitute promising targets for cervical cancer 
therapy, since several oncogenic alterations were 
already identified that can be potentially predictive of 
response to anti-RTKs and anti-signaling protein 
drugs [9, 10]. 
Inhibitors of HER family receptors, or ErBb, have 
been among the most successful examples of targeted 
cancer therapies to date, including antibodies (e.g., 
trastuzumab and cetuximab) and small-molecule 
tyrosine kinase inhibitors (e.g., erlotinib, gefitinib, 
lapatinib and allitinib) [11-13]. A large number of 
novel HER2-targeted agents are also in clinical trials 
[14]. 
HER receptors belong to family I of RTKs which 
includes EGFR, HER2, HER3 and HER4. These RTKs 
recognize 13 different but structurally related growth 
factors like EGF. However, for HER2, no soluble 
ligand has yet been identified [15]. Amplification, 
overexpression, and co-expression of the HER family 
receptors have been implicated in the genesis or 
progression of human mammary, ovarian, gastric and 
brain cancers [14, 15]. Anti-HER2 therapy is currently 
approved for breast, gastric, and gastroesophageal 
cancers that overexpress HER2 protein or carry 
amplified HER2 gene. HER2 aberrations have also 
been reported in other diverse malignancies. Indeed, 
about 1–37% of tumors, such as bladder, colon, 
endometrium, germ cell, glioblastoma, head and neck, 
liver, lung, ovarian, pancreas, and salivary duct, 
harbor HER2 aberrations [14]. 
In cervical cancer, HER receptor expression has 
been reported to be upregulated, but its prognostic 
and therapeutic value remains unclear [11, 16-22]. 
Some clinical trials are using RTK inhibitors in the 
treatment of cervical cancer patients, but the expected 
benefits have not been demonstrated, mainly because 
patients were not pre-selected for the molecular 
alterations in the targets of interest [23]. Hence, 
besides bevacizumab, no other targeted therapies, 
including those designed to target RTKs, approval for 
cervical cancer treatment [3, 24, 25].  
Thus, in this work we aimed to identify RTK 
targets, mainly HER receptors, for personalized 
therapeutic options for cervical cancer and to 
elucidate the putative molecular mechanisms 
underlying the response to the tested inhibitors. 
Materials and Methods 
Tissue samples 
In the present study 229 cervical cancer tissues, 
which included 194 adenocarcinomas and 35 
adenosquamous carcinomas, were analyzed. The 
paraffin samples included in tissue microarrays 
(TMA) were retrieved from the files from School of 
Medicine of the Federal University of Goiás (Goiânia, 
Goias State, Brazil). All histopathological diagnoses 
were reviewed by the authors and categorized 
according to the WHO classification [26]. All patients 
with cervical cancer were of Brazilian origin, with a 
mean age of 47 years (range 21-84 years). Follow-up 
data was available for 137 patients, and collected 
through direct interview with patients or their 
relatives and by review of in-hospital patient files. The 
median follow-up time was 96.19±11.23 months 
(range, 1–780 months).  
Cell lines and Cell culture 
Four cervical cancer cell lines, HeLa, SiHa, 
C-33A and Caski, were used in the present study. 
HeLa cell line was a gift by Drª Elsa Logarinho (IBMC, 
Portugal), SiHa, C-33A and Caski cell lines were 
kindly provided by Drª Luisa Villa (INCT-HPV, 
Brazil) [27]. All cell lines were grown and maintained 
at 37ºC and 5% CO2 in Dulbecco’s Modified Eagle’s 
Medium (DMEM 1x, High Glucose; Gibco, 
Invitrogen) supplemented with 10% Fetal Bovine 
Serum (FBS; Gibco, Invitrogen) and 1% 
penicillin/streptomycin solution (Gibco, Invitrogen).  
Downregulation of HIF1-α was performed with 
Silencer Select Validated siRNAs from Ambion 
(siRNA ID #42840) as well as with a non-targeting 
control siRNA (Silencer Select Negative Control No.1 
siRNA, 4390843), using Lipofectamine RNAiMAX 
(13778-075, Invitrogen) as a transfection reagent, 
according to the manufacturer’s instructions, and as 
described [28]. 
Authentication of cell lines was performed in our 
lab by short tandem repeat (STR) DNA typing 
according to the International Reference Standard for 
Authentication of Human Cell Lines using a panel of 8 
(D5S818, D13S317, D7S820, D16S539, vWA, TH01, 
TPOX and CSF1P0) STR loci plus gender 
determination (AMEL) [29]. The genotyping 
confirmed the identity of all cell lines. 
Drugs 
Cediranib (CD), sunitinib (SU), imatinib (IM), 
erlotinib (ER), lapatinib (LA), allitinib (AST1306 - 
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AST), MK2206 (MK) and selumetinib (SE) were 
obtained from Selleck Chemicals (Houston, USA) and 
2-Deoxy-D-glucose (2-DG) was purchased from 
Sigma-Aldrich (Sintra, Portugal). All the drugs were 
prepared as stock solutions in dimethyl sulfoxide 
(DMSO) and stored at -20ºC, as described [30]. The 
2-DG was always freshly prepared and diluted in 
water to a 10 mM stock solution. In all experimental 
conditions the drugs were diluted in 0.5% FBS culture 
medium. The vehicle control was also used in all 
experiments. 
Real-time quantification of HER2/neu gene 
amplification 
For HER2 gene amplification detection, DNA 
from paraffin tumors was isolated as previously 
described [6]. The copy numbers of the gene were 
detected using the LightMix® Kit HER2/neu (Cat. 
number 40-0333-16) from Roche Molecular 
Biochemicals, following the manufacture 
recommendations. The calculation of the relative 
amounts of HER2 DNA compared to the reference 
gene DNA was performed, and the final results were 
expressed as a ratio of HER2:reference gene copies in 
the sample, normalized with the ratio of 
HER2:reference gene copies in the calibrator DNA. 
The ratio HER2: reference gene copies in the calibrator 
DNA was set to one. A ratio of < 2.0 was considered to 
be negative for HER2 over-amplification, a ratio of ≥ 
2.0 was assumed to be positive for HER2 
amplification. 
Immunohistochemistry analysis (IHC) 
Histological slides with 4 µm-thick tissue 
sections were subjected to immunohistochemistry 
analysis according to the streptavidin-biotin 
peroxidase complex system (UltraVision Large 
Volume Detection System Anti-Polyvalent, HRP; 
LabVision Corporation), as previously described [27]. 
Briefly, deparaffinized and rehydrated slides were 
submitted heat-induced antigen retrieval for 20min at 
98ºC with 10mM citrate buffer (pH 6.0) for GLUT1, 
HIF-1α and Ki-67, or in microwave at 600W in 1 mM 
EDTA buffer (pH 7.8) for HER4, and treated with 
pronase (1mM) for 30 min at 37°C for HER2, HER3 
and EGFR. The sources of and their dilutions were as 
follows: EGFR (Zymed, dilution 1:100); HER2 (Cell 
Signaling, dilution 1:100); HER3 (Cell Signaling, 
dilution 1:100); HER4 (Cell Signaling, dilution of 1:50); 
GLUT1 (Abcam, dilution 1:500); HIF-1α (BD 
Biosciences, dilution 1:100); and Ki-67 (Gennova, 
dilution 1:100). All primary antibodies were incubated 
ON at 4ºC. The secondary biotinylated goat 
anti-polyvalent antibody was applied for 10 minutes 
followed by incubation with the 
streptavidin-peroxidase complex. The immune 
reaction was visualized by 3, 3’-Diamonobenzidine 
(DAB) as a chromogen. All sections were 
counterstained with Gill-2 haematoxylin. For negative 
controls, primary antibodies were omitted and 
replaced by a universal negative control antibody 
(CEA, rabbit anti-human, DAKO Corporation). 
Breast carcinoma tissues were used as positive 
controls. Stained slides were evaluated and then 
photographed using a bright field microscope 
Olympus BX61. 
The immunostaining of the tissues was 
semi-quantitatively evaluated by an experienced 
professional considering extension and intensity of 
staining for EGFR, HER2, HER3, HER4 and GLUT1, 
as previously described [31]. The score for 
immunoreactive extension was as follows: score 0, 0% 
of immunoreactive cells; score 1, <5% of immuno- 
reactive cells; score 2, 5%–50% immunoreactive cells; 
and score 3, >50% of immunoreactive cells. For 
intensity, the score was as follows: 0, negative; 1, 
weak; 2, intermediate; and 3, strong. The final score 
was defined as the sum of these 2 semiquantitative 
scores, and for statistical analysis, final score >3 was 
considered to be positive. Cellular localization of 
staining (cytoplasm/membrane/nucleus) of the 
studied markers was also evaluated. For the nuclear 
markers Ki-67 and HIF-1α, the sections were scored 
semi-quantitatively as follows [6, 27]: (−), 0% of 
immunoreactive cells; (+), <5% of immunoreactive 
cells; (++), 5–50% of immunoreactive cells; and (+++), 
>50% of immunoreactive cells. Samples with scores 
(−) and (+) were considered negative, and those with 
scores (++) and (+ + +) were considered positive. 
Immunofluorescence 
The cells were plated until ~60% of confluency 
on glass slides and allowed to adhere overnight. 
Afterwards, the cells were fixed in methanol 100% at 
-20ºC and blocked in a solution of PBS containing 10% 
FBS for 30 min. The primary antibodies used were the 
same as for the IHC, and incubated overnight at 4ºC. 
The FITC Alexa Fluor- conjugated secondary 
antibodies (Molecular Probes, Invitrogen) were used 
at a dilution of 1:500. For negative controls, primary 
antibodies were omitted and replaced by a universal 
negative control antibody (CEA, rabbit anti-human, 
DAKO Corporation). 
The nuclei were stained with DAPI and slides 
were covered using VECTSHIELD mounting solution. 
The slides were examined and images were obtained 
by fluorescence microscopy (BX16; Olympus). 
Western blot and human RTK arrays 
For in vitro assays, the cells were plate in a 6 well 
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plate at a density of 8x105 cells per well and allowed to 
adhere for at least 24 hours, then serum starved for 2 
hours and incubated with the drugs for 2 hours, as 
previous described [30, 32]. When necessary, the cells 
were also stimulated with 10 ng/ml of EGF for 15 
minutes before the end of the time point. To assess 
apoptosis, cells were incubated with only one 
concentration of each drug and incubated for 24 
hours. At the indicated time points, the cells were 
washed and scraped in cold PBS and lysed in buffer, 
as previously described [30]. For the in vivo assays, the 
treated tumors at the desired concentration of the 
drugs for four days, were divided in half washed in 
PBS and lysed in the same buffer as for cell lines. 
Western blotting was done using standard 10% 
SDS-PAGE, loading 40 µg of protein per lane. All 
antibodies were used as recommended by the 
manufacturers, and were the same as described for 
IHC and IF. All other antibodies (apoptosis and 
intracellular pathways assessment) were used as 
previously described [30]. Anti-GAPDH (Santa Cruz 
Biotechnology, dilution 1:2000) was used as a loading 
control. 
For the human RTK arrays, 500 μg of fresh 
protein lysates, before and after treatment with the 
drugs, were incubated overnight at 4ºC with 
nitrocellulose membranes dotted with duplicated 
spots for 42 anti-RTK and control antibodies. Bound 
phospho-RTKs were incubated with a pan 
anti–phosphotyrosine-HRP antibody for 2 h at room 
temperature [30].  
Blots detection was done by chemiluminescence 
(Thermo Scientific Pierce ECL Western Blotting) using 
the ChemiDoc™ XRS+ System (Bio-Rad). 
Cell viability assay 
To determine the concentration at which 50% of 
the cell growth is inhibited by drug treatment (IC50 
concentration), cells were plated in 96-well plates at a 
density of 4x103 cells per well and allowed to adhere 
overnight in DMEM containing 10% FBS. 
Subsequently, the cells were treated with increasing 
concentrations of the drugs or with DMSO alone, both 
diluted in 0.5% FBS culture medium to a final 
concentration of 1% DMSO. When necessary the cells 
were incubated simultaneously with 2.5 µM of 
selumetinib or MK2206, and 1.5 mM 2-DG. After 72 
hours, cell viability was quantified using the Cell 
Titer96 Aqueous cell proliferation assay (Promega). 
The results were expressed as the mean percentage ± 
SD of viable cells relative to the DMSO alone 
(considered as 100% viability). The IC50 concentration 
was calculated by nonlinear regression analysis using 
GraphPad Prism software. 
To assess the effect of a fixed concentration of the 
drug in cellular viability over time, the cells were 
plated onto 96-well plates at a density of 2x103 cells 
per well and allowed to adhere overnight in complete 
DMEM medium. Next, the viable cells were 
quantified using the Cell Titer96 Aqueous cell 
proliferation assay (Promega), and used for time point 
0. Then, the cells were incubated with fixed 
concentrations of the drugs or with DMSO alone, both 
diluted in 0.5% FBS culture medium to a final 
concentration of 1% DMSO, over 24, 48 and 72 hours. 
At the end of each time point, cell viability was again 
assessed using the Cell Titer96 Aqueous cell 
proliferation assay. The results were calibrated to the 
starting viability (time 0h, considered as 100% 
viability) and expressed as the mean ± SD. Both assays 
were performed in triplicate at least three times [30]. 
Wound healing migration assay 
The cells were seeded in 6-well plates and 
cultured to at least 95% confluency, as described [27, 
30]. Monolayer cells were washed with PBS and 
scraped with a plastic 200 µL pipette tip and then 
incubated with fresh DMEM medium without serum. 
The ‘‘wounded’’ areas were photographed by phase 
contrast microscopy at 24, 48 and 72 hours’ time 
points. The relative migration distance was calculated 
by the following formula: percentage of wound 
closure (%) = 100 (A–B)/A, where A was the width of 
cell wounds before incubation, and B was the width of 
cell wounds after incubation. Results were expressed 
as the mean ± SD. The assay was done in triplicate at 
least three times. 
Clonogenicity assay 
The cells (1x103) were seeded in 12-well plates 
and incubated for 24h to adhere. Medium was 
replaced with DMEM-0.5 with or without drugs and 
the cells incubated for 10-15 days, with medium 
renewal after every 3 days. The colonies were stained 
with 5% Giemsa for 45min and manually counted. 
Results were expressed as the mean colonies ± SD. 
The assay was done in triplicate at least three times. 
Extracellular lactate measurements 
Cells were plated in 48-well plates at a density of 
3x104 cells per well and allowed to adhere overnight. 
Lactate content was analyzed in cell culture medium 
after 24h of drugs treatment, using a commercial kit 
(Spinreact), as described [33]. The total protein 
(expressed as total biomass) was assessed using the 
sulforhodamine B assay (SRB, Sigma-Aldrich). Results 
were expressed as mean mg of lactate/ total biomass 
± SD and adjusted for the control (considered as 1). 
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In vivo Chick chorioallantoic membrane 
(CAM) assay 
To assess in vivo tumor proliferation we used the 
CAM assay as previously described [27, 30], with 
some modifications. On day 9 of development, the 
cells (2x106 cells) were suspended in matrigel and 
incubated on the CAM to allow the formation of a 3D 
tumor, for the next 4 days. On day 13 of development 
the tumors were treated with the desired drugs for 4 
more days. On day 17 of development, the tumor 
formed was photographed in ovo and ex ovo using a 
stereomicroscope (Olympus S2x16), and the perimeter 
of the tumor was measured using Cell B software 
(Olympus). The results were expressed as the mean 
perimeter ± SD. The vasculature area was calculated 
using AngioTool software (National Cancer Institute), 
and the results expressed as vessels area mean ± SD 
(pixel). The tumors were then lysed or embedded in 
paraffin and processed for Western blot and 
histological analysis, respectively, as described above. 
In Silico analysis 
The cBioPortal for Cancer Genomics 
(http://www.cbioportal.org) is a repository of cancer 
genomics datasets [34, 35] that was used to investigate 
the molecular profiles of HER2, HER3, HER4, and 
EGFR in cervical cancer. In the present study it was 
used for mutations, putative copy number alterations 
(CNA), transcriptomic, and survival data from the 
provisional TCGA cervical squamous cell carcinoma 
and endocervical adenocarcinoma (CESC) project 
with 307 samples currently available. The repository 
had samples containing both sequencing and CNA 
data, corresponding to 191 patients by August 2015. 
According to the TCGA guidelines 
(http://cancergenome.nih.gov/publications/publica
tionguidelines). This dataset has no limitations or 
restrictions.  
The frequency of alterations of the genes across 
the set of samples was summarized in the format of 
OncoPrint plots. The mutation mapper tool of 
cBioPortal was used to plot the distribution of 
mutations. Significant CNA was obtained by GISTIC 
method. The dysregulation of gene expression was 
determined by a Z-score threshold of ± 2.0 when 
compared with normal samples. Finally, the genes 
analyzed alone and in combinations were considered 
for associations with overall survival using the 
Kaplan–Meier method with log rank testing with p < 
0.05. 
Statistical analysis 
Correlations between proteins expression and 
clinical data from patients were performed using the 
chi-square test (χ2-test). Cumulative survival 
probabilities were calculated using the Kaplan-Meier 
method. Differences between survival rates were 
tested with the log-rank test. Multivariate analysis 
was done using the Cox proportional hazards model. 
The statistical analysis was performed using SPSS 
software for Windows, version 17.0. For in vitro and in 
vivo assays, single comparisons between the different 
conditions studied were done using Student’s t test, 
and differences between groups were tested using 
two-way analysis of variance (ANOVA). Statistical 
analysis was done using Graph Pad Prism version 5. 
The level of significance in all the statistical analysis 
was set at p<0.05. 
Results 
Overexpression of HER receptors in cervical 
cancer tissues as an independent prognostic 
marker 
Immunohistochemistry analysis was carried out 
to determine the frequency of HER protein receptor 
expression and distribution in a series of cervical 
cancer. As shown in Figure 1A, EGFR positivity was 
found in the cytoplasm, membrane, and stroma of 
tumor cells, in 18.8% (33/176) of all tumors. A positive 
HER2 expression was observed in the membrane and 
cytoplasm of tumor cells in 53.5% (91/170) of the 
cases, whereas HER3-specific staining was present in 
the membrane, cytoplasm, stroma and in a few nuclei 
of the tumor cells in 74.7% (124/166) of patients. 
Finally, only 23.4% (37/158) of cases exhibited lower 
positivity (all with the score<4) for HER4 in the 
cytoplasm, nuclei, and stroma of the tumor cells. With 
the exception of HER2 and HER3 that were 
co-expressed in 61.7% (71/115) of the cases (p=0.007), 
no significant correlations were found between the 
co-expression of various receptors. 
The clinical impact of the expression of HER 
family of receptors in cervical cancer patients was 
evaluated in relation with the available clinical 
features (Supplementary Table 1). EGFR was 
differentially expressed (p<0.05) between the two 
histological types in study, being associated with the 
adenosquamous subtype (44.4%). HER3, was 
significantly more expressed in older patients (>47 
years old), and it was also associated with the 
presence of metastasis (p<0.05) (Supplementary 
Table 1). 
Using the Kaplan-Meier analysis (Table 1), we 
detected a tendency (p=0.07) for an association 
between HER2 positivity and poor prognosis by 
univariate analysis. Importantly, stratifying the levels 
of HER2 expression by negative (score 0 and 2), 
moderate positivity (score 3 and 4) and 
overexpression (score 5 and 6), we observed a 
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significant association (p=0.014) between the 
overexpression of HER2 and poor survival (Figure 
1B). This association was also observed by 
multivariate analysis where metastasis and HER2 
overexpression constituted independent prognostic 
markers for cervical cancer patients (Table 1). 
HER2 overexpression is strongly associated with 
HER2 gene amplification in breast cancer patients 
[36]. We used quantitative PCR in a subset of cases 
(n=17) to screen for the presence of HER2 
amplification in cervical cancer. Eight of the 17 
samples evaluated had HER2 overexpression by IHC 
and HER2 amplification was detected in only 1 case 
(12.5% - 1/8); all other cases showed absence of HER2 
gene amplification. 
 
 
Figure 1. Molecular characterization of HER receptors in human cervical cancer specimens. (A) Immunohistochemistry analysis of HER family 
receptors in representative cervical cancer tissues. All pictures were taken at 400x magnification. (B) Overall survival according to HER2 expression in cervical 
cancer. Cases with HER2 overexpression (p= 0.014) have a poor prognosis. (C) OncoPrint plot of TCGA CESC data generated by cBioPortal showing CNA, 
mutation and mRNA frequency of alterations of HER2, HER3, HER4 and EGFR in a total of 190 patients analyzed (only 66 cases are represented). (D) Boxplot of 
TCGA CESC data from cBioPortal showing protein upregulation relative to amplification of ERBB2. (E) Survival analysis of ERBB2 mRNA of TCGA CESC patients 
with Kaplan Meier plot generated using cBioPortal (p<0.05). 
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Table 1: Univariate and multivariate analyses between the 
clinicopathological features and overall survival of the patients. 
Parameter N Univariate Analysis Multivariate Analysis 
(months ± SD) p HR (95% CI) p 
Metastasis      
 Absent 24 586.2 ± 68.2  1  
  Present 4 17.5 ± 3.8 0.001 0.097 (0.02-0.42) 0.002 
HER2 expression      
 Negative 24 508.5 ± 76.7  1  
  Positive 11 120.3 ± 41.8 0.071 3.4 (0.9-12.2) 0.059 
 
 
 
In silico validation of the role of HER receptors 
in cervical cancer 
We extended our analysis by corroborating with 
the microarray profiling datasets of cervical cancer 
tissues available from the cBioPortal for Cancer 
Genomics and from the TCGA database. As is seen in 
Figure 1C, HER receptors are altered with respect to 
mRNA expression, gene copy numbers and mutations 
with the most frequent alteration (13% - 25/190) 
detected in HER2. EGFR and HER2 presented 
mutations in more than one tyrosine kinase 
phosphorylation site (Supplementary figure S1), 
highlighting their potential use as molecular targets 
for tyrosine kinase inhibitors. Furthermore, HER2 
gene amplification present in 3% of the cases (6/190) 
appeared to be exclusively present in the cases with 
HER2 mRNA upregulation and protein 
overexpression (Figure 1C and D). 
Importantly, we were able to confirm in a 
different cohort of patients that HER2 overexpression, 
even at mRNA level, was significantly associated with 
poor survival in cervical cancer patients (Figure 1E). 
HER receptors are targetable proteins on 
cervical cancer cell lines 
To determine whether RTKs, especially the HER 
family of receptors, could be targetable proteins for 
cervical cancer therapy, we initially characterized the 
in vitro models for the expression and activation of 
these proteins. According to the Cancer Cell Lines 
Project Database (COSMIC - 
http://cancer.sanger.ac.uk/cell_lines), there are no 
genetic mutations of RTKs on HeLa, SiHa, Caski and 
C-33A cervical cancer cell lines. We used a 
phospho-RTK array to identify the basal levels of RTK 
activation and interestingly found that only the HER 
family of receptors was activated (Figure 2A). These 
results were also validated by Western blotting 
showing the basal activation levels of EGFR on SiHa, 
HeLa and Caski cell lines, and of HER4 and HER2 on 
C-33A and Caski cell lines, respectively (Figure 2B). 
Upon EGF stimulation, phosphorylated EGFR was 
observed in all cell lines, and phosphorylated HER2 
was detectable in SiHa, HeLa and Caski cell lines 
(Figure 2B). Since plasma membrane localization is 
important for predicting the therapeutic efficacy, we 
confirmed the surface localization of HER receptors 
by immunofluorescence (Figure 2C).  
To evaluate whether the HER family of receptors 
can be specifically and efficiently targeted on cervical 
cancer, we screened the sensitivity of several cell lines 
to different pan-RTKs inhibitors (Table 2 and 
supplementary Figure 2A). As summarized in Table 2, 
all cell lines were very responsive to the two pan-HER 
inhibitors used, allitinib (AST1306 - an irreversible 
inhibitor) and lapatinib (a reversible inhibitor). 
Compared to the other inhibitors, which were 
designed to target only EGFR (erlotinib) or different 
RTKs such as KIT, PDGFRA and VEGFR2 (cediranib, 
sunitinib and imatinib), the IC50 values for AST1306 
and lapatinib were significantly lower. Next, to gain a 
better insight into the mechanism of cytotoxicity of 
the inhibitors, we studied the effect of each drug in 
HER signaling pathways inhibition (Figure 2A and 
2D). It appeared that the highest cytotoxic effect of 
AST1306 and lapatinib could be mainly due to its 
specificity to concomitantly inhibit the 
phosphorylation of HER2, HER4, EGFR and 
intracellular signaling pathways such as ERK and 
AKT (summarized on Table 2). Interestingly, at higher 
doses, cediranib was a potent inhibitor on our panel of 
cell lines, especially for HeLa cells (Table 2 and 
supplementary Figure 2A). Western blotting revealed 
that cediranib was able to inhibit HER2 in Caski cells 
(Figure 2D) and ERK in all cell lines without 
EGF-stimulation (supplementary Figure 2B), partly 
explaining its potency. We have previously reported 
that cediranib is a very potent inhibitor of ERK and 
can also block other receptors, such as EGFR, AXL 
and EphA [30]. It is of note that erlotinib, which 
efficiently inhibited the activation of both EGFR and 
HER2 under EGF-stimulated conditions (Figure 2D), 
was non-toxic for HeLa and SiHa cell lines (Table 2). 
These two cell lines appeared to be less dependent on 
EGF for intracellular activation, mainly via AKT 
pathway, than the other cell lines (Supplementary 
Figure 2C). In fact, potential secondary bypass 
mechanisms of intracellular signaling activation have 
been identified as inducing cellular resistance to 
specific inhibitors, which might be the case for HeLa 
and SiHa cells. To clarify whether the concomitant 
inhibition of RTKs and intracellular pathways are 
crucial for an effective response to these inhibitors, we 
combined lapatinib with AKT (MK2206) and MAPK 
(selumetinib) pathway inhibitors in C-33A and SiHa 
cell lines with different responses and dependencies 
on these pathways. Both drugs were able to lower the 
IC50 value of lapatinib, but the effect was more 
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pronounced in the less responsive and EGF 
dependent cell line, SiHa. Furthermore, the combined 
inhibition of EGFR (with lapatinb) and AKT pathway 
(with MK2206) was more pronounced increasing 
almost twice the response of SiHa cells to lapatinib 
(Supplementary Figure 2D). Thus, we can conclude 
that HER receptors present on cervical cancer cell 
lines are good theranostic markers for HER specific 
inhibitors (such as AST1306 and lapatinib) and the 
cellular response to these drugs can be improved by 
concomitantly inhibiting the receptors and their 
intracellular signaling pathways. 
 
 
 
Figure 2. HER inhibitors are targeted drugs for cervical cancer cell lines. (A) Phospho-RTK arrays were done at basal conditions for all cell lines, and after 
2 hours treatment with 1.5 µM of AST1306 (AST) and lapatinib (LA) for Caski and C-33A cell lines. Each RTK is represented in duplicat in the arrays (two spots 
side-by-side), and three pairs of phospho-tyrosine positive controls are located in the corners of each array. (B-C) Characterization of cervical cancer cell lines for 
HER receptors expression at basal conditions before and after stimulation with 10ng/ml EGF by 15 minutes (B) by western blot and (C), by immunofluorescence. D) 
Western blot analysis of HER receptors and ERK/AKT intracellular pathways for all cell lines treated with 2.5 µM of all drugs for a period of 2 hours with 10ng/ml EGF 
for 15 minutes. 
 
 
Table 2: Inhibitory effect of anti-RTK drugs on cervical cancer cell lines. 
  Caski  C-33A  SiHa HeLa 
  IC50 (µM ± SD) Signalling 
Inhibition* 
IC50 (µM ± SD) Signalling 
inhibition* 
IC50 (µM ± SD) Signalling 
 inhibition 
IC50 (µM ± 
SD) 
Signalling 
inhibition 
Cediranib (CD) LR HER2 LR n.i LR n.i S n.i 
(2.73 ± 0.48) (4.26 ± 0.08) (7.22 ± 1.23) (0.53 ± 0.49) 
Sunitinib (SU) LR n.i LR n.i LR n.i LR n.i 
(3.23 ± 0.91) (9.96 ± 5.48) (10.21 ± 3.24) (4.77 ± 1.35) 
Imatinib (IM) LR n.i LR n.i LR n.i LR n.i 
(>20) (>20) (>20) (>20) 
Erlotinib (ER) S EGFR/HER2 S EGFR/ERK LR EGFR/HER2 LR EGFR/HER2 
(2.41 ± 1.19) (2.30 ± 0.89) (>20) (>20) 
Lapatinib (LA) S EGFR/HER2/AKT S HER4/EGFR/ERK S EGFR/HER2/AKT S EGFR/HER2 
(0.54 ± 0.023) (1.78 ± 0.43) (2.36 ± 0.63) (2.19 ± 0.98) 
AST1306 (AST) S EGFR/HER2/AKT/ERK S HER4/EGFR/ERK S EGFR/HER2/AKT/ERK S EGFR/HER2 
(0.024 ± 0.023) (0.10 ± 0.12) (2.31 ± 0.28) (2.34 ± 0.41) 
*Data from Figure 2A and 2D; IC
50 
≤ 2.5µM – Sensitive (S); IC
50 
> 2.5µM – Lower Responsive (LR); n.i – No Inhibition. 
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Inhibition of HER receptors can reverse 
aggressiveness of cervical cancer cells in vitro 
and in vivo 
To determine the biological impact of HER 
pan-inhibitors on viability, migration and 
proliferation of cells both in vitro and in vivo, we 
choose a highly sensitive cell line, C-33A and a 
relatively less sensitive, SiHa cell line. The viability 
assay overtime showed that lapatinib and especially 
AST1306, even at lower doses, were more efficient 
than erlotinib due to their strong cytotoxic effect on 
both cell lines (Figure 3A). The PARP cleavage 
measurement revealed the efficacy of AST1306 was 
also due to its enhanced capability of apoptosis 
induction (Figure 3B). Furthermore, using 
clonogenicity and migration assays, which measure 
important features of cancer cell aggressiveness, we 
have observed a significant inhibitory effect of 
AST1306 in both cell lines (Figure 3C and 3D), while 
erlotinib and lapatinib were effective only in the more 
sensitive C-33A cell line (Figure 3C and 3D). 
We further performed an in vivo CAM assay by 
inducing the formation of 3D tumors that were highly 
aggressive and exhibited histological features that 
were similar to those observed in human tumors with 
high rates of angiogenesis and collapsed blood vessels 
(Figure 4A and Supplementary Figure 3). In 
agreement with the in vitro assays, we found that 
AST1306 and lapatinib treatment reduced the size of 
the tumors formed by injecting C-33A cells but not the 
SiHa cells (Figure 4B), although both inhibitors were 
anti-angiogenic for SiHa-induced tumors 
(Supplementary Figure 3B). Histological analysis 
revealed that both drugs were biological active in 
suppressing tumorigenesis in both models. There was 
a lack of cellular viability and integrity in the treated 
tumors with formation of large necrotic areas (Figure 
4A) and a decrease in the expression of the respective 
HER targets and in the staining of number/intensity 
of Ki-67 positive cells (Figure 4C and Supplementary 
Figure 3C). Therefore, even when the tumor mass was 
not reduced, probably because the experimental 
window in the CAM assay was too small, induction of 
cell death and inhibition of proliferation was observed 
in vivo, highlighting the potential usage of pan-HER 
inhibitors for cervical tumors. 
 
 
Figure 3. Biological effect of HER inhibitors in vitro (C-33A and SiHa). (A) Cell viability was measured at 24, 48, and 72 hours by MTS after treatment with 
erlotinib (ER), AST1306 (AST) and lapatinib (LA). (B) Apoptosis was measured by Western blotting for PARP cleavage (C-PARP) after 24 hours treatment with AST, 
LA and ER. (C) Colony formation was measured by a clonogenicity assay. At the left are representative pictures of the assays done in 12-well plates (D) Migration 
was measured by wound healing migration assay after 72 hours of treatment with drugs. At the left are representative pictures of wounds (40x magnification). The 
results are expressed in relation to the DMSO control as the mean ± SD. 
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Figure 4. In vivo effect of HER inhibitors on cervical cancer. (A) After tumor formation at day 13 of development, the treatment with AST and LA (1.5 µM) 
was performed for 4 days. Representative pictures (16X magnification) of CAM assay ex ovo at day 17 with the respective H&E pictures (40X magnification), where 
the necrosis areas (N) are marked. (B) Tumor growth was measured as described in materials and methods in an average of 15 tumors per condition. The results are 
expressed as the mean ± SD. (C) Representative pictures of the immunohistochemistry (IHC) analysis for HER4, EGFR and ki-67 of the tumors (200X magnification).  
 
Combination of lapatinib with metabolic 
blockers can prevent the putative in vivo 
resistance of cervical tumors to HER inhibitors  
The resistance to the RTK inhibitors is a 
significant clinical problem, since even patients who 
initially respond to the therapy have a high 
probability to develop acquired resistance to the 
drugs with time [37]. A mechanism that has been 
recently associated with resistance to conventional 
chemotherapy or oncogene-targeted therapies is the 
deregulated glucose metabolism, in which HIF-1α has 
a crucial role. The clinical potential of targeted 
therapies can be enhanced by combining them with 
glycolysis inhibitors [38]. There is compelling 
evidence linking HER inhibitors’ response to the 
regulation of energy metabolism in HER-dependent 
tumors [38-40]. To address whether glucose 
metabolism could be putatively involved in the 
response of cervical cancer cells to HER inhibitors, we 
focused on SiHa cells which have been well 
characterized previously and showed relatively low 
responsive to HER inhibitors.  
We first interrogated the expression level of 
HIF-1α upon treatment with HER inhibitors. Using 
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IHC on SiHa-tumor sections, we observed that HIF-1α 
expression varies with the inhibitors. There was a 
tendency of decreased expression in the tumors 
treated with AST1306, whereas lapatinib-treated 
tumors maintained high levels of HIF-1α (Figure 5A 
and 5B). These experiments were also performed 
using the C-33A cell line-derived tumors where the 
increase in HIF-1α expression was even more 
pronounced, probably because its basal expression 
level was very low (Supplementary Figure 4A and 
4B).  
Then, we explored whether changes occur in the 
cellular metabolism, by measuring the levels of 
extracellular lactate, upon treatment of cells with the 
drugs. We observed a significant increase in the 
production of lactate only upon lapatinib treatment 
(Figure 5C), a phenomenon not observed in the 
sensitive cell line C-33A (Supplementary Figure 4C). It 
was not clear whether the greater efficacy of AST1306 
and lapatinib in C-33A cells compared to that in SiHa 
cells could be related to their basal expression levels 
of HIF-1α. To explore this, we re-assessed the 
sensitivity of SiHa cells to lapatinib upon HIF-1α 
downregulation and found that in fact the cells 
became more responsive in the absence of HIF-1α 
(Figure 5D). However, we also observed that besides 
maintaining or increasing the expression levels of 
HIF-1α in both cell lines, lapitinib increases the 
glycolytic metabolism only in the less responsive SiHa 
cells. It has been reported that alterations in the 
glucose metabolism ultimately dictate the resistance 
phenotype of the cells to the RTK targeted therapies 
[38]. We therefore tested whether the inhibition of the 
lactate production in lapatinib-treated tumors can 
revert the sensitivity of cells to this drug. We used 
combinations of lapatinib with a non-metabolizable 
glucose analogue, 2-Deoxy-D-glucose (2-DG) (Figure 
5D), at a dose that alone does not significantly affect 
the cellular viability (Supplementary Figure 4D). The 
combination resulted in a significant reduction of the 
lactate level (Figure 5C and Supplementary Figure 
4C) and was much more efficient in sensitizing cells to 
lapatinib treatment than the inhibition of HIF-1α 
expression alone (Figure 5D). The same synergetic 
effect was observed for C-33A cells (Supplementary 
Figure 4E). However, since the cells were already 
highly sensitive to lapitinib, it is plausible that the 
combination of the drug with 2-DG could be indicated 
for tumors less sensitive to lapatinib and for which 
metabolic changes can be expected upon treatment, as 
was the case with SiHa cells. The combinations of 
2-DG with AST1306 were also effective 
(Supplementary Figure 4F). 
 
 
Figure 5. Effective combinations to improve lapatinib therapy response in vitro. (A) Representative pictures of the immunohistochemistry (IHC) analysis 
for HIF1-α in SiHa-induced tumors (200X magnification). (B) Graphic representation of the scores obtained in IHC analysis of in vivo tumors for HIF1-α. The 
horizontal lines represent the mean score obtained in the samples for each condition. (C) Quantification of extracellular lactate levels in vitro, in SiHa cell line after 
24 hours of treatment with 1.5 µM of AST or LA, 1.5 mM of 2-DG or LA in combination with 2-DG. (D) At the left is the Western blot analysis of HIF1-α in SiHa 
cells transfected with siRNA for HIF1-α or with the scramble control. At the right is the cell viability measured in vitro by MTS after 72 hours of treatment to 
determine the half maximal inhibitory concentrations (IC50) for lapatinib before and after siRNA for HIF1-α transfection or in combination with 2-DG. All 
experiments were done at least three times in triplicate and the graphs are presented as the mean ± SD relative to DMSO alone (100% viability). 
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Figure 6. In vivo efficacy of lapatinib combination with the glucose analogue 2-DG. After tumor formation, at day 13 of development, treatment with AST 
and LA (1.5 µM) or 2-DG (1.5 mM) alone and in combination with LA was done for 4 days. The tumors were divided in half for simultaneous histological and Western 
blot analyses. (A) Representative pictures of the immunohistochemistry (IHC) analysis for EGFR, Ki-67, GLUT1 and HIF-1α, with the respective H&E for the in vivo 
tumors: CTR (tumor 7), AST (tumor 3), LA (tumor 4), LA+2-DG (tumor 14) and 2-DG (tumor 8) (200X magnification). (B) Western blot analysis of the same tumors 
shown in Figure 6A. (C) Quantification of tumors perimeter and (D) vessels area as described in materials and methods. The results are expressed as the mean ± SD. 
 
To validate our results in vivo, we induced SiHa 
tumors in CAM and treated with HER inhibitors 
alone or in combination with 2-DG (Figure 6). The 
tumors were divided in half for simultaneous 
histological and Western blot analysis. With this 
approach, we confirmed in vivo that both drugs 
(lapatinib and AST1306) were effective in the 
reduction of EGFR phosphorylation and activation of 
ERK/AKT pathways (Figure 6A and 6B). Once more, 
AST1306 proved to be more cytotoxic, since the 
majority of cells exhibited an apoptotic phenotype, 
with no proliferating cells (Figure 6A), total cleavage 
of PARP, and absence of HIF-1α positive cells (Figure 
6B). In contrast, upon lapatinib treatment, the tumors 
retained some activation levels of EGFR and signaling 
pathways as well as a considerable number of Ki-67 
positive cells (Figure 6A and 6B). Importantly, while 
expression of GLUT1 was maintained at high levels 
under all conditions, expression of HIF-1α varied 
considerably (Figure 6A) with overexpression in the 
lapatinib-treated tumors. The increased expression of 
HIF-1α was abolished after the combined treatment 
with 2-DG (Figure 6A and B) resulting in a significant 
reduction in tumor size and vasculature, while 2-DG 
alone has no major impact on tumor growth despite 
being a potent anti-angiogenic drug (Figure 6C and 
6D). 
Thus, in conjunction with glucose inhibitors the 
responsiveness of cervical cancer cells to lapatinib 
increased both in vitro and in vivo. This appears to be a 
good strategy to prevent the putative HIF1-α-induced 
resistance due to long term exposure to lapatinib of 
cervical cancer cells.  
Discussion 
Cervical cancer is a major women health 
problem worldwide [2]. The addition of platin-based 
chemotherapy to primary radiotherapy has increased 
the 5-year survival of advanced-stage cervical cancer 
patients, which is, however, still only 66% [2]. In view 
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of this, there is a critical need to identify molecularly 
targeted therapies that prolong life but do not create 
additional toxicities further compromising the 
patients’ quality of life [37, 41]. However, no targeted 
drugs have been developed specifically for cervical 
cancer, mainly because data on targetable genetic 
alterations in these tumors are far behind the 
knowledge for other tumor types. Recent 
whole-exome sequencing studies have provided 
evidence for the presence of targetable oncogenic 
mutations that warrant further investigation on the 
feasibility of specific targeted therapies for these 
tumors [9, 42]. In the present work, we aimed to study 
the frequency of alterations in the ErbB family of 
receptors and to explore their potential for specific 
targeting in cervical cancer. 
Initially, we analyzed a large series of cervical 
cancer samples by immunohistochemistry. Our 
results revealed that HER2 was frequently expressed 
(53.5%), whereas EGFR was least frequently 
expressed (23.4%) in this set of cervical tumors. This 
could be explained by the fact that EGFR is 
preferentially expressed in squamous tumors, as also 
reported by other studies [7, 19, 43, 44] and the 
majority of our cases were adenocarcinomas. 
Importantly, we observed that HER2 overexpression 
constituted an independent prognostic marker for 
cervical cancer patients. Since squamous carcinomas 
are more common, the majority of the studies were 
conducted on this histologic type [45, 46], making a 
comparison with our work difficult. ErbB receptor 
overexpression is generally considered in the 
literature as a rare event in cervical cancer with highly 
discrepant frequencies among studies. HER2 
expression varies between 16-77% [44, 47, 48] and is 
associated with poor prognosis in some studies, while 
others failed to find such clinical association [49-52]. 
EGFR expression in squamous cervical cancer varies 
from 6% to 90% [53] and its prognostic role remains 
controversial [16, 17]. Among other HER receptors, 
HER3 was overexpressed in 74.4% (58/78) of patients 
and was correlated with poor prognosis [54], whereas 
HER4 was overexpressed in 79.5% of squamous 
tumors with no association with clinical parameters 
[54]. In our study, HER3 overexpression was detected 
in 75% of the tumors and was associated with poor 
prognosis markers such as age and metastasis. In 
contrast, only 23% of the tumors were positive for 
HER4 in our study. 
Our immunohistochemistry findings were 
further corroborated by in silico analysis. HER 
receptors were differentially altered in terms of 
mRNA expression, gene copy numbers, and 
mutations with HER2 being the most frequently 
altered (13% - 25/190) gene. EGFR and HER2 
harbored mutations in more than one tyrosine kinase 
phosphorylation site. These results were supported by 
comprehensive genetic landscape analysis studies, 
which described HER2 amplification in a small 
percentage of cervical cancer patients and evidence of 
HER2 activation by somatic mutation, amplification, 
and human papilloma virus (HPV) integration in 
cervical cancer [9, 42]. Recent work by Xiang et al. also 
reported the presence of HER2 (4.2%) and EGFR 
(0.4%) oncogenic mutations [42].  
We further characterized four commercial cell 
lines (Caski, SiHa, HeLa and C-33A) and found that 
only HER family of receptors was activated in these 
cell lines, an observation that was mostly validated 
using other methods. A substantially higher 
proportion of cervical cancer cell lines, either 
established from fresh tumors or from commercial 
sources, were reported to express HER2 when 
evaluated by flow cytometry [55]. It was also reported 
that HER2-positive cells may have a selective 
advantage over HER2-negative cells both in vitro and 
in vivo [46], and that HER2-negative cervical cancers 
can be transformed into HER2-expressing ones when 
they recur or metastasize [53, 55, 56].  
We screened the sensitivity of cervical cancer cell 
lines to different pan-RTKs inhibitors and observed 
that the drugs that target one or more HER receptors 
(such as erlotinib, AST1306 and lapatinib), were more 
potent than the ones designed to target different RTKs 
such as KIT, PDGFRA and VEGFR2 (cediranib, 
sunitinib and imatinib). Importantly, we found that 
all cell lines were very responsive to the two pan-HER 
inhibitors used, AST1306 (allitinib - an irreversible 
agent) and lapatinib, probably due to their ability to 
inhibit the phosphorylation of HER2, HER4, and 
EGFR and its downstream signaling pathways. 
Hence, we showed that pan-HER inhibitors are 
effective anti-tumorigenic drugs for HER positive 
cervical tumors, both in vitro and in vivo.  
None of the inhibitors designed to target HER 
receptor received approval for cervical cancer 
treatment. Pre-clinical studies showed that the growth 
of cervical cancer cell lines expressing HER2 was 
inhibited when incubated with trastuzumab [55]. 
Importantly, it was found that afatinib - also an 
irreversible agent as allitinib- was highly effective 
against HER2-mutated cervical cancer in vitro [57]. 
Another study reported that combination therapy 
with trastuzumab and lapatinib induced significant in 
vivo anti-tumor activity and suggested that 
HER2-amplified cervical cancer patient-derived 
xenograft models may accurately predict the 
outcomes and treatment response to these inhibitors 
[58]. In one case report, a HER2-negative cervical 
cancer exhibited HER2 positivity after peritoneal 
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metastasis and the patient had a dramatic treatment 
response after combined trastuzumab and lapatinib 
treatment [14]. The RTK inhibitors have not shown 
the expected benefits in clinical trials mainly because 
the patients were not pre-screened or pre-selected for 
the molecular alterations in the targets of interest [23]. 
Consistent with our in vitro results that showed the 
absence of KIT, PDGFRA and VEGFR2 on cervical cell 
lines, no evidence of response or stabilization of 
disease was observed after imatinib or sunitinib 
treatment in the clinical trials [59, 60]. In contrast, 
cediranib had a significant efficacy when added to 
carboplatin and paclitaxel in the treatment of 
metastatic or recurrent cervical cancer though it was 
accompanied by an increased toxic effect [61]. Also, 
the results of targeted therapy based on EGFR 
blockage in cervical cancer have not been as 
promising as those obtained for other tumors with 
tyrosine kinase inhibitors such as gefitinib and 
erlotinib [3, 62, 63]. A Phase II, open-label study of 
specific inhibitors of HER2 protein, pazopanib or 
lapatinib, in patients with advanced and recurrent 
cervical cancer showed that pazopanib was well 
tolerated and resulted in improved progression free 
survival. The response rates were 9% and 5% for 
pazopanib and lapatinib, respectively [64]. Although 
this study was not powered for overall survival, an 
updated publication of this trial reported a median OS 
of 44.1 weeks for lapatinib and of 49.7 weeks for 
patients who received pazopanib [65]. However, no 
phase III trials are yet registered with these agents. 
Taken together, these data indicate that cell growth 
regulation by the HER pathways could be a dominant 
oncogenic driver in cervical cancer. 
One of the major challenges in oncology research 
is to overcome the inherent resistance to molecular 
targeted therapies following prolonged treatment 
periods. Secondary activation of intracellular 
signaling pathways upon inhibition of RTKs is 
considered a potential bypass mechanism underlying 
cellular resistance RTK inhibitors. Another 
mechanism that was recently associated with 
resistance to classical chemotherapy or 
oncogene-targeted therapies is the deregulated 
glucose metabolism [38]. It has been shown that 
resistance to known oncogene targeted therapies can 
be driven by enhanced glycolytic metabolism by the 
resistant cells in contrast to the sensitive cells [40, 
66-70]. The HIF-1α, as well as glucose transporters are 
considered as the possible predictive factors 
regulating this “reprogramming” in the glycolytic 
metabolism [40, 66-69]. For cervical cancer in 
particular, overexpression of HIF-1α has also been 
identified as an independent negative prognostic 
marker [71]. However, the relevance of tumor 
metabolism in the modulation of cervical tumors 
response to targeted therapies remains to be 
elucidated. 
Herein, we found by immunohistochemistry that 
HIF-1α expression was maintained or increased upon 
lapatinib treatment in vivo, and that HIF-1α 
downregulation sensitized the cells to lapatinib. Also, 
in the low responsive cells to this drug we detected an 
increased lactate production upon treatment, 
indicating reprogramming of glycolytic metabolism. 
This phenomenon was also reported for breast cancer 
[40]; Komurov and colleagues found that lapatinib 
(EGFR and HER2 inhibitor) induction of toxicity in 
HER2-positive breast cancer cells was associated with 
glucose deprivation, and prolonged lapatinib 
treatment led to acquired resistance that was 
characterized by increased expression of networks 
involved in glucose deprivation or hypoglycemic 
response [40]. Furthermore, it has been shown that 
cetuximab (monoclonal antibody for EGFR) treatment 
downregulated glycolysis through HIF-1α inhibition, 
which was dependent on effective inhibition of 
PI3K/AKT pathway in non-small-cell lung carcinoma 
[67, 68]. In contrast, colorectal cancer models with 
acquired resistance to cetuximab had a significantly 
higher production of lactate [72], and resistant cells of 
head and neck squamous cell carcinoma models 
overexpressed HIF-1α and were highly glycolytic [73]. 
Moreover, overexpression of HIF-1α conferred 
cellular resistance to cetuximab-induced apoptosis in 
sensitive lung adenocarcinoma cells [67, 68]. 
In our in vivo experiments, the increased 
expression of HIF-1α upon lapatinib treatment was 
abolished after the combined treatment with 2-DG, 
which resulted in a significant reduction in the tumor 
vasculature and size. There was no major impact on 
tumor growth of the treatment with 2-DG alone which 
was potent anti-angiogenic drug. Interestingly, in 
lung adenocarcinoma, targeting glycolysis with 2-DG 
was an effective therapeutic option to overcome the 
limited efficacy of afatinib in patients with EGFR 
resistant mutations [39].  
In conclusion, in this study, we performed the 
most comprehensive analysis of HER family receptors 
alterations in cervical adenocarcinoma. We observed 
the presence of HER protein overexpression, mainly 
HER2, which was an independent prognostic marker 
for these patients. By using HER specific inhibitors in 
both in vitro and in vivo assays, we provided evidence 
for an important biological and oncogenic role of 
these proteins in cervical cancer cells. More 
significantly, we demonstrated that the combination 
of lapatinib with 2-DG increased the in vitro and in 
vivo responsiveness of cervical cancer cells to 
lapatinib. This may likely be a good strategy to 
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prevent a putative HIF1-α-induced resistance due to 
long term exposure to lapatinib. Thus, we propose the 
usage of HER family inhibitors in association with 
glucose metabolism blockers as potentially effective 
anti-cancer agents for the treatment of cervical cancer 
patients. 
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